Valius Health, Inc., operating as Valius Sciences, is a San Francisco cancer diagnostics company offering comprehensive multi-omic tumor profiling for patients with rare, aggressive, or treatment-resistant cancers. It maps a patient's tumor across DNA, RNA, and protein using whole genome sequencing, bulk and single-cell RNA sequencing, spatial RNA analysis, protein testing, and ctDNA analysis to surface therapeutic targets that routine diagnostics miss. Results are paired with an ongoing scientific partnership in which bioinformaticians and oncology scientists work with the patient and their treating physician to translate findings into treatment strategies. The company has worked with patients across 25 cancer types and raised more than $10 million in a Series Seed round led by 8VC and Basis Set Ventures announced in April 2026.
A deliberately maximalist diagnostic panel that profiles every biological layer of a tumor regardless of cancer type, sold direct-pay and bundled with hands-on scientific interpretation for patients who have exhausted standard options.